J
John L. Grutsch
Researcher at Eli Lilly and Company
Publications - 17
Citations - 509
John L. Grutsch is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Aryl & Indole test. The author has an hindex of 9, co-authored 17 publications receiving 497 citations.
Papers
More filters
Journal ArticleDOI
Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
James A. Monn,Matthew John Valli,Steven Marc Massey,Marvin M. Hansen,Kress Thomas Joseph,James P. Wepsiec,Harkness Allen Robert,John L. Grutsch,Rebecca A. Wright,Bryan G. Johnson,Sherri L. Andis,Ann E. Kingston,Rosemarie Tomlinson,Richard A. Lewis,Kelly R. Griffey,Joseph P. Tizzano,Darryle D. Schoepp +16 more
TL;DR: Evaluation of the functional effects of (-)-9 and (-)-10 on second-messenger responses in nonneuronal cells expressing human mGlu receptor subtypes demonstrated each to be a highly potent agonist for group II mGLU receptors.
Journal ArticleDOI
Synthesis of aryl- and heteroaryl[a]pyrrolo[3,4-c]carbazoles.
Concha Sanchez-Martinez,Margaret M. Faul,Chuan Shih,Kevin A. Sullivan,John L. Grutsch,Jeremy T. Cooper,Stanley P. Kolis +6 more
TL;DR: Synthesis of aryl- and hetero[a]pyrrolo[3,4-c]carbazoles by photochemical oxidation and Heck cyclization and the regiochemistry of the cyclization can be controlled using the Heck reaction.
Journal ArticleDOI
Synthetic approaches to indolo[6,7-a]pyrrolo[3,4-c]carbazoles: potent cyclin D1/CDK4 inhibitors.
Margaret M. Faul,Thomas A. Engler,Kevin A. Sullivan,John L. Grutsch,Marcella T. Clayton,Michael John Martinelli,Joseph Matthew Pawlak,Michael E. LeTourneau,D. Scott Coffey,Steven Wayne Pedersen,Stanley P. Kolis,Kelly Wayne Furness,Sushant Malhotra,Rima S. Al-awar,James Edward Ray +14 more
TL;DR: The chemistry developed enabled introduction of functionality (-OR, NR(2)) at C(12) and N(13) facilitating structure-activity relationship (SAR) evaluation of this indolocarbazole platform.
Journal ArticleDOI
1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors.
Rima S. Al-awar,James Edward Ray,Kyle Andrew Hecker,Jianping Huang,Philip Parker Waid,Chuan Shih,Harold B. Brooks,Charles D. Spencer,Scott A. Watkins,Bharvin K. R. Patel,Nancy B. Stamm,Catherine A. Ogg,Richard M. Schultz,Eileen L. Considine,Margaret M. Faul,Kevin A. Sullivan,Stanley P. Kolis,John L. Grutsch,Sajan Joseph +18 more
TL;DR: The synthesis and kinase inhibitory activity of a series of novel 1,7-annulated indolocarbazoles 6 and 16 exhibited potent inhibitoryactivity against cyclin-dependent kinase 4 and good antiproliferative activity in a human colon carcinoma cell line.
Journal ArticleDOI
Synthesis of indolo[2,3-a]carbazole glycoside analogs of rebeccamycin: inhibitors of cyclin D1-CDK4
Margaret M. Faul,Kevin A. Sullivan,John L. Grutsch,Leonard L. Winneroski,Chuan Shih,Concha Sanchez-Martinez,Jeremy T. Cooper +6 more
TL;DR: The synthesis and structure-activity relationships of a new series of indolo[2,3]-a ] carbazole glycosides, analogs of rebeccamycin, derived from the natural sugars (glucoses, fucose, mannose, xylose, rhamnose and galactose) is described in this paper.